risperidone has been researched along with Child Development Disorders, Pervasive in 72 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Child Development Disorders, Pervasive: Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 9.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 9.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 8.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 7.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 7.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| "This study identified subtypes of aggression in a sample of 206 children with autism spectrum disorder (ASD) who participated in 2 risperidone trials." | 5.19 | Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. ( Aman, MG; Arnold, LE; Bearss, K; Carroll, D; Hallett, V; Handen, BL; Johnson, C; Lecavalier, L; McCracken, JT; McDougle, CJ; Scahill, L; Sukhodolsky, DG; Swiezy, N; Tierney, E; Vitiello, B, 2014) |
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 5.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD)." | 5.11 | Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. ( Carroll, A; Dunbar, F; Orlik, H; Schulz, M; Shea, S; Smith, I; Turgay, A, 2004) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 5.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "To review the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autism spectrum disorder (ASD)." | 4.83 | Role of risperidone in children with autism spectrum disorder. ( Chavez, B; Chavez-Brown, M; Rey, JA, 2006) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| " Prolactin levels, hyperprolactinemia, risperidone levels, and 9-hydroxyrisperidone levels were assessed and the participants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of the dopamine D2 receptor gene." | 3.79 | The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. ( Boot, AM; Buitelaar, JK; Franke, B; Galesloot, TE; Roke, Y; van Harten, PN, 2013) |
| "To report a case of risperidone-induced Pisa syndrome in a patient with multiple sclerosis (MS) that resolved with lurasidone, recurred with chlorpromazine, and was complicated by possible drug-drug interactions." | 3.79 | Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine. ( Diefenderfer, LA; Iuppa, CA, 2013) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Although hyperprolactinemia is a common side effect during risperidone treatment in adult patients, no information is available on young children." | 3.71 | Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. ( Cosenza, A; Masi, G; Mucci, M, 2001) |
| "8 years) with bipolar disorder (25 mixed and 3 hypomanic) who had been treated with risperidone were identified." | 3.70 | Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. ( Biederman, J; Frazier, JA; Kim, GS; Meyer, MC; Shapiro, S; Spencer, TJ; Wilens, TE; Wozniak, J, 1999) |
| "Autism spectrum disorder is characterized by difficulty with social communication and restricted, repetitive patterns of behavior, interest, or activities." | 2.53 | Autism Spectrum Disorder: Primary Care Principles. ( Sanchack, KE; Thomas, CA, 2016) |
| "This article gives an overview of the pharmacokinetic profile of risperidone and a comprehensive review of treatment studies regarding the use of risperidone in ASD." | 2.52 | Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder. ( Dietrich, A; Dinnissen, M; Hoekstra, PJ; van den Hoofdakker, BJ, 2015) |
| "Risperidone has been the best studied among these medications." | 2.43 | Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. ( Dinca, O; Paul, M; Spencer, NJ, 2005) |
| " No correlation was found between risperidone dosage and either risperidone or drug metabolite plasma levels." | 1.40 | CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. ( Bar-Chaim, A; Benveniste-Levkovitz, P; Berkovitch, M; Britzi, M; Gabis, LV; Soback, S; Youngster, I; Zachor, DA; Ziv-Baran, T, 2014) |
| "Outcome measures were the Childhood Autism Rating Scale, the Children's Psychiatric Rating Scale, Clinical Global Impression (improvement score), and the Children's Global Assessment of Functioning." | 1.31 | Risperidone monotherapy in preschool children with pervasive developmental disorders. ( Cosenza, A; De Vito, G; Masi, G; Mucci, M, 2001) |
| "Weight gain was observed in 5 of 6 patients, with a median increase of 5." | 1.30 | Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. ( Armenteros, J; Munoz-Silva, DM; Pataki, C; Perry, R; Silva, RR, 1997) |
| "Risperidone was initiated at a starting dose of 0." | 1.29 | Use of risperidone in pervasive developmental disorders: a case series. ( Fisman, S; Steele, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (12.50) | 18.2507 |
| 2000's | 23 (31.94) | 29.6817 |
| 2010's | 40 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Margari, L | 1 |
| Matera, E | 1 |
| Craig, F | 1 |
| Petruzzelli, MG | 1 |
| Palmieri, VO | 1 |
| Pastore, A | 1 |
| Margari, F | 1 |
| Bachmann, CJ | 1 |
| Manthey, T | 1 |
| Kamp-Becker, I | 1 |
| Glaeske, G | 1 |
| Hoffmann, F | 1 |
| Nurmi, EL | 1 |
| Spilman, SL | 1 |
| Whelan, F | 1 |
| Scahill, LL | 1 |
| Aman, MG | 10 |
| McDougle, CJ | 17 |
| Arnold, LE | 8 |
| Handen, B | 6 |
| Johnson, C | 5 |
| Sukhodolsky, DG | 3 |
| Posey, DJ | 4 |
| Lecavalier, L | 7 |
| Stigler, KA | 7 |
| Ritz, L | 4 |
| Tierney, E | 5 |
| Vitiello, B | 8 |
| McCracken, JT | 6 |
| Roke, Y | 2 |
| van Harten, PN | 2 |
| Franke, B | 2 |
| Galesloot, TE | 1 |
| Boot, AM | 2 |
| Buitelaar, JK | 5 |
| Ameis, SH | 1 |
| Corbett-Dick, P | 1 |
| Cole, L | 1 |
| Correll, CU | 1 |
| Carroll, D | 1 |
| Hallett, V | 2 |
| Handen, BL | 1 |
| Swiezy, N | 2 |
| Bearss, K | 5 |
| Scahill, L | 11 |
| Iuppa, CA | 1 |
| Diefenderfer, LA | 1 |
| Wink, LK | 2 |
| Early, M | 2 |
| Schaefer, T | 1 |
| Pottenger, A | 1 |
| Horn, P | 1 |
| Erickson, CA | 4 |
| Adler, BA | 1 |
| Shaffer, R | 1 |
| Minshawi, N | 1 |
| Youngster, I | 1 |
| Zachor, DA | 1 |
| Gabis, LV | 1 |
| Bar-Chaim, A | 1 |
| Benveniste-Levkovitz, P | 1 |
| Britzi, M | 1 |
| Soback, S | 1 |
| Ziv-Baran, T | 1 |
| Berkovitch, M | 1 |
| Hoekstra, PJ | 5 |
| Dinnissen, M | 1 |
| Dietrich, A | 1 |
| van den Hoofdakker, BJ | 1 |
| Wong, IC | 1 |
| Hsia, Y | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Fung, LK | 1 |
| Mahajan, R | 1 |
| Nozzolillo, A | 1 |
| Bernal, P | 1 |
| Krasner, A | 1 |
| Jo, B | 1 |
| Coury, D | 1 |
| Whitaker, A | 1 |
| Veenstra-Vanderweele, J | 3 |
| Hardan, AY | 1 |
| Sanchack, KE | 1 |
| Thomas, CA | 1 |
| Dziura, J | 4 |
| Butter, E | 4 |
| Sukhodolsky, D | 1 |
| Mulick, J | 1 |
| Stigler, K | 1 |
| Wagner, A | 2 |
| Swiezy, NB | 4 |
| Sukhodolsky, DD | 2 |
| Ramadan, Y | 1 |
| Pozdol, SL | 2 |
| Nikolov, R | 2 |
| Kohn, AE | 2 |
| Koenig, K | 3 |
| Hollway, JA | 2 |
| Korzekwa, P | 2 |
| Gavaletz, A | 2 |
| Mulick, JA | 2 |
| Hall, KL | 1 |
| Trollinger, S | 1 |
| Yu, S | 3 |
| van Haaren, F | 1 |
| Lemmon, ME | 1 |
| Gregas, M | 1 |
| Jeste, SS | 1 |
| Troost, PW | 3 |
| Lahuis, BE | 3 |
| Mulder, H | 1 |
| Mulder, EJ | 1 |
| Anderson, GM | 2 |
| Minderaa, RB | 3 |
| McPheeters, ML | 2 |
| Warren, Z | 2 |
| Sathe, N | 1 |
| Bruzek, JL | 1 |
| Krishnaswami, S | 1 |
| Jerome, RN | 1 |
| Banaschewski, T | 1 |
| Poustka, L | 1 |
| Holtmann, M | 1 |
| Calarge, CA | 1 |
| Miller, del D | 1 |
| Lit, L | 1 |
| Sharp, FR | 1 |
| Bertoglio, K | 1 |
| Stamova, B | 1 |
| Ander, BP | 1 |
| Sossong, AD | 1 |
| Hendren, RL | 1 |
| Matson, JL | 1 |
| Sipes, M | 1 |
| Fodstad, JC | 1 |
| Fitzgerald, ME | 1 |
| Farmer, C | 1 |
| Eugene Arnold, L | 2 |
| Johnson, CR | 1 |
| Demb, H | 1 |
| Valicenti-McDermott, M | 1 |
| Navarro, A | 1 |
| Ayoob, KT | 1 |
| Ishitobi, M | 1 |
| Hiratani, M | 1 |
| Kosaka, H | 1 |
| Takahashi, T | 1 |
| Mizuno, T | 1 |
| Asano, M | 1 |
| Murata, T | 1 |
| Tomoda, A | 1 |
| Wada, Y | 1 |
| Frazier, TW | 1 |
| Swiezy, NG | 1 |
| Grinnon, S | 1 |
| Okada, T | 1 |
| Hasanzadeh, E | 1 |
| Mohammadi, MR | 1 |
| Ghanizadeh, A | 1 |
| Rezazadeh, SA | 1 |
| Tabrizi, M | 1 |
| Rezaei, F | 1 |
| Akhondzadeh, S | 1 |
| Venkat, A | 1 |
| Jauch, E | 1 |
| Russell, WS | 1 |
| Crist, CR | 1 |
| Farrell, R | 1 |
| Chadman, KK | 1 |
| Guariglia, SR | 1 |
| Yoo, JH | 1 |
| Nightingale, S | 1 |
| Dove, D | 1 |
| Taylor, JL | 1 |
| Sathe, NA | 1 |
| Yui, K | 1 |
| Li, X | 1 |
| Humphries, K | 1 |
| Wilson, K | 1 |
| Deng, Y | 1 |
| Tenback, D | 1 |
| Rapin, I | 1 |
| Masi, G | 4 |
| Cosenza, A | 4 |
| Mucci, M | 4 |
| Brovedani, P | 2 |
| Findling, RL | 1 |
| McNamara, NK | 1 |
| Shea, S | 1 |
| Turgay, A | 1 |
| Carroll, A | 1 |
| Schulz, M | 1 |
| Orlik, H | 1 |
| Smith, I | 1 |
| Dunbar, F | 1 |
| Kastner, TA | 1 |
| Bober, D | 1 |
| Sabzwari, U | 1 |
| Star, JE | 1 |
| Dinca, O | 1 |
| Paul, M | 1 |
| Spencer, NJ | 1 |
| Hellings, JA | 1 |
| Zarcone, JR | 1 |
| Valdovinos, MG | 1 |
| Reese, RM | 1 |
| Gaughan, E | 1 |
| Schroeder, SR | 1 |
| Chavez, B | 1 |
| Chavez-Brown, M | 1 |
| Rey, JA | 1 |
| Williams, SK | 1 |
| Dimitropoulos, A | 1 |
| Cronin, P | 1 |
| Grados, M | 1 |
| Ghuman, J | 1 |
| Lam, KS | 1 |
| McGough, J | 1 |
| Althaus, M | 1 |
| Hermans, MH | 1 |
| van Engeland, H | 1 |
| Carr, JE | 1 |
| LeBlanc, LA | 1 |
| Gadow, KD | 1 |
| Williams White, S | 1 |
| Purdon, SE | 1 |
| Lit, W | 1 |
| Labelle, A | 1 |
| Jones, BD | 1 |
| Holmes, JP | 2 |
| Bronson, MR | 1 |
| Volkmar, FR | 1 |
| Price, LH | 2 |
| Cohen, DJ | 2 |
| Demb, HB | 1 |
| Fisman, S | 2 |
| Steele, M | 2 |
| Pipher, B | 1 |
| Perry, R | 1 |
| Pataki, C | 1 |
| Munoz-Silva, DM | 1 |
| Armenteros, J | 1 |
| Silva, RR | 1 |
| Carlson, DC | 1 |
| Pelton, GH | 1 |
| Toren, P | 1 |
| Laor, N | 1 |
| Weizman, A | 1 |
| Frazier, JA | 1 |
| Meyer, MC | 1 |
| Biederman, J | 1 |
| Wozniak, J | 1 |
| Wilens, TE | 1 |
| Spencer, TJ | 1 |
| Kim, GS | 1 |
| Shapiro, S | 1 |
| De Vito, G | 1 |
| Buckley, PF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial[NCT03432832] | 113 participants (Actual) | Interventional | 2018-01-30 | Completed | |||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| The Effectiveness of an Attention-based Intervention for School Aged Autistic Children With Anger Regulating Problems: a Randomized Controlled Trial[NCT05221515] | 51 participants (Actual) | Interventional | 2011-01-01 | Completed | |||
| Effect of PLAY Project Intervention Program on Children With Autism Spectrum Disorder: A Multi-center, Randomized Control Study in China[NCT05531669] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder[NCT01631851] | 9 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Randomized Trial of Parent Training for Young Children With Autism[NCT01233414] | 180 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| Development and Validation of a System for the Anticipation of Challenging Behaviors of People With Autism Spectrum Disorder Based on a Smart Shirt: a Mixed-method Design[NCT05340608] | 51 participants (Actual) | Observational | 2022-06-01 | Completed | |||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Assessing the Feasibility, Acceptability, and Preliminary Efficacy of an Adaptive Intervention Approach for Children With Autism and Disruptive Behavior: A Pilot Study[NCT04204226] | 42 participants (Actual) | Interventional | 2019-12-17 | Completed | |||
| Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study[NCT00261508] | Phase 3 | 80 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
18 reviews available for risperidone and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder.
Topics: Animals; Antipsychotic Agents; Child Development Disorders, Pervasive; Disease Management; Drug Eval | 2015 |
Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Child Development D | 2016 |
Autism Spectrum Disorder: Primary Care Principles.
Topics: Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Autism Spectrum Disorder; Autistic Disorder; | 2016 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil | 2008 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
A systematic review of medical treatments for children with autism spectrum disorders.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Dis | 2011 |
Issues in the management of challenging behaviours of adults with autism spectrum disorder.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Behavior Therapy; Child; Child Development D | 2011 |
[The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Clomipramine; Cognitive Behavio | 2011 |
Care of the patient with an autism spectrum disorder by the general physician.
Topics: Adolescent; Antipsychotic Agents; Caregivers; Child; Child Development Disorders, Pervasive; Child, | 2012 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous | 2012 |
Medications for adolescents and young adults with autism spectrum disorders: a systematic review.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2012 |
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; | 2004 |
Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child Development Disorders, Perv | 2005 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
Role of risperidone in children with autism spectrum disorder.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Double-Blind | 2006 |
Autism spectrum disorders in early childhood: an overview for practicing physicians.
Topics: Asperger Syndrome; Autistic Disorder; Behavior Therapy; Behavioral Medicine; Child; Child Developmen | 2007 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
17 trials available for risperidone and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems.
Topics: Adolescent; Aggression; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Child; | 2014 |
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
Topics: Adolescent; Aggression; Behavior Therapy; Child; Child Development Disorders, Pervasive; Combined Mo | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial.
Topics: Adolescent; Antipsychotic Agents; Behavior Therapy; Child; Child Behavior Disorders; Child Developme | 2009 |
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.
Topics: Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Body Mass Index; Child; Child D | 2010 |
Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child Development Disorders, Perv | 2012 |
Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.
Topics: Adaptation, Psychological; Adolescent; Antipsychotic Agents; Asperger Syndrome; Autistic Disorder; C | 2012 |
A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.
Topics: Administration, Oral; Antipsychotic Agents; Child; Child Behavior; Child Development Disorders, Perv | 2012 |
Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child Develo | 2012 |
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; D | 2013 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; | 2005 |
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
Topics: Antipsychotic Agents; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasi | 2006 |
Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Child; Child Behavior Disorders; Child Deve | 2006 |
Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, | 2007 |
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
Topics: Adolescent; Adolescent Behavior; Child; Child Behavior; Child Development Disorders, Pervasive; Dopa | 1997 |
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Aggression; Antipsychotic Agents; Autistic Disorder; Child Developme | 1998 |
Open trial of risperidone in 24 young children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2001 |
37 other studies available for risperidone and Child Development Disorders, Pervasive
| Article | Year |
|---|---|
Tolerability and safety profile of risperidone in a sample of children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit | 2013 |
Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Autistic Disorder; Central Nervous System Stimula | 2013 |
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Amidohydrolases; Antipsychotic Agents; Bo | 2013 |
The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Topics: Adolescent; Alleles; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chil | 2013 |
Decision making and antipsychotic medication treatment for youth with autism spectrum disorders: applying guidelines in the real world.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child Development Disorders, Pervasive; Child | 2013 |
Risperidone-induced Pisa syndrome in MS: resolution with lurasidone and recurrence with Chlorpromazine.
Topics: Adult; Antipsychotic Agents; Child Development Disorders, Pervasive; Chlorpromazine; Gait Ataxia; Hu | 2013 |
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Child Development Disorders, | 2014 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child D | 2015 |
CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; C | 2014 |
Risperidone for non-psychotic disorders in paediatric patients: which child is to benefit?
Topics: Antipsychotic Agents; Child Development Disorders, Pervasive; Cytochrome P-450 CYP2D6; Female; Human | 2014 |
Authors' response to Bachmann and Hoffman's comments on psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.
Topics: Child Development Disorders, Pervasive; Female; Humans; Male; Methylphenidate; Risperidone; Valproic | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Risperidone and parent training in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Health Education; Humans; Paren | 2010 |
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Benzodiazepines; Central Nervous System Sti | 2010 |
Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; F | 2011 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervas | 2011 |
Gene expression in blood is associated with risperidone response in children with autism spectrum disorders.
Topics: Antipsychotic Agents; Biomarkers, Pharmacological; Child; Child Development Disorders, Pervasive; Ch | 2012 |
The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.
Topics: Antipsychotic Agents; Body Weight; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
Topics: Adolescent; Aripiprazole; Child; Child Development Disorders, Pervasive; Drug Substitution; Female; | 2012 |
Friends not foes: combined risperidone and behavior therapy for irritability in autism.
Topics: Adaptation, Psychological; Antipsychotic Agents; Child Behavior Disorders; Child Development Disorde | 2012 |
Autism spectrum disorders.
Topics: Adolescent; Aripiprazole; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials | 2012 |
[Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders].
Topics: Administration, Inhalation; Antipsychotic Agents; Arachidonic Acid; Aripiprazole; Child Development | 2012 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
The autistic-spectrum disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2002 |
A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2003 |
Methylphenidate an effective treatment for ADHD?
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Auti | 2004 |
Use of risperidone in developmentally disabled children.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Diagnosis, D | 2005 |
Risperidone in a very young child with PDD.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2005 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Risperidone in the treatment of pervasive developmental disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Perv | 1994 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Use of risperidone in pervasive developmental disorders: a case series.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Dopamine; Female; H | 1996 |
Risperidone in PDD.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Humans; Risperidone | 1998 |
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
Topics: Adolescent; Anger; Child; Child Development Disorders, Pervasive; Dopamine Antagonists; Female; Huma | 1997 |
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; C | 1999 |
Risperidone monotherapy in preschool children with pervasive developmental disorders.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Child Development Disorder | 2001 |
Prolactin levels in young children with pervasive developmental disorders during risperidone treatment.
Topics: Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2001 |